Publications by authors named "Mark Faber"

Claim this Profile
S
Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies.
Jeffrey Baron, Daniel Appiah, Mark G Faber, Han Yu, Tara Cronin

Leuk Lymphoma· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.
Hassan Awada, Mina Abdelmalek, Tara Cronin, Jeffrey Baron, Zakariya Kashour, Mark Faber

Blood Cancer J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy.
Jurjen Versluis, Manu Pandey, Yael Flamand, J Erika Haydu, Roger Belizaire, Mark Faber

Blood Adv· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incremental Hemodialysis: What We Know so Far.
Vivek Soi, Mark D Faber, Ritika Paul

Int J Nephrol Renovasc Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience.
Mark G Faber, Chong Wang, Sruthi Kommi Reddy, Alison Meagher, Amy Early

Lung Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutant - and -Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy.
Abhay Singh, Nuria Mencia-Trinchant, Elizabeth A Griffiths, Alaa Altahan, Mahesh Swaminathan, Mark G Faber

JCO Precis Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States.
Abhay Singh, Megan M Herr, Elizabeth A Griffiths, Amanda Przespolewski, Mark G Faber

Sci Rep· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone.
Abhay Singh, Swapna Thota, Terrence Bradley, Elizabeth A Griffiths, Mark G Faber

Clin Lymphoma Myeloma Leuk· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of vascular disease in myelodysplastic syndromes.
Mark G Faber, David R Lloyd, Abhay Singh, Jeffrey Baron, Amanda Przespolewski

EJHaem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.
Zachary Schlei, Wei Tan, Mark G Faber, Hongbin Chen, Alison Meagher

Clin Lung Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.
Daniel W Coyne, Seth Goldberg, Mark Faber, Cybele Ghossein, Stuart M Sprague

Clin J Am Soc Nephrol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of further decline in renal function after the use of oral sodium phosphate or polyethylene glycol in patients with a preexisting glomerular filtration rate below 60 ml/min.
Stefan Russmann, Lois Lamerato, Stephen P Motsko, John C Pezzullo, Mark D Faber

Am J Gastroenterol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute renal failure in cardiothoracic surgery patients: what is the best definition of this common and potent predictor of increased morbidity and mortality.
Anthony Falvo, H Mathilda Horst, Ilan Rubinfeld, Dione Blyden, Mary-Margaret Brandt, Mark D Faber

Am J Surg· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting outcomes of peritoneal-dialysis-associated peritonitis based on dialysate white blood cell count.
Mark D Faber

Nat Clin Pract Nephrol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and management of enteric disease and abdominal catastrophe in peritoneal dialysis patients with peritonitis.
Mark D Faber, Jerry Yee

Adv Chronic Kidney Dis· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fivefold reduction in peritonitis using a multifaceted continuous quality initiative program.
Diane Borg, Anupkumar Shetty, Deborah Williams, Mark D Faber

Adv Perit Dial· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of adequate solute clearance in obese patients on peritoneal dialysis: a cross-sectional study.
Yugo Shibagaki, Mark D Faber, George Divine, Anupkumar Shetty

Am J Kidney Dis· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis